Press Release: PHRI : Bayer Forms Collaboration With Academic and Governmental Institutions for Global Phase III Study to Evaluate Xarelto®▼(rivaroxaban) in Patients With a Recent Embolic Stroke of Undetermined Source

NEWBURY, England, January 27, 2015 /PRNewswire/ -- PRESS RELEASE FOR UK TRADE MEDIA ONLY In addition, Xarelto®▼(rivaroxaban) label now includes guidance for use in patients with atrial fibrillation undergoing cardioversion Bayer HealthCare today announces a...